Tarvacin

Peer Reviewed News for Medical Professionals

Medical Research Health Special Topics World

Home

	Health
	Aging
	Asian Health
	Events
	Fitness
	Food & Nutrition
	Happiness
	Men's Health
	Mental Health
	Occupational Health
	Parenting
	Public Health
	Sleep Hygiene
	Women's Health

	Healthcare
	Africa
	Australia
	Canada Healthcare
	China Healthcare
	India Healthcare
	New Zealand
	South Africa
	UK
	USA
	World Healthcare

	Latest Research
	Aging
	Alternative Medicine
	Anaethesia
	Biochemistry
	Biotechnology
	Cancer
	Cardiology
	Clinical Trials
	Cytology
	Dental
	Dermatology
	Embryology
	Endocrinology
	ENT
	Environment
	Epidemiology
	Gastroenterology
	Genetics
	Gynaecology
	Haematology
	Immunology
	Infectious Diseases
	Medicine
	Metabolism
	Microbiology
	Musculoskeletal
	Nephrology
	Neurosciences
	Obstetrics
	Ophthalmology
	Orthopedics
	Paediatrics
	Pathology
	Pharmacology
	Adrenergics
	Analgesics
	Anti Cancer Drugs
	Rituximab
	Tarvacin
	Anti-Clotting Drugs
	Anti-Inflammatory
	Antibiotics
	Anticholesterol
	Antihypertensives
	Antivirals
	Fatty Acids
	Hypnotics
	Metals
	PPI
	Surfactants
	Varenicline
	Physiology
	Physiotherapy
	Psychiatry
	Radiology
	Rheumatology
	Sports Medicine
	Surgery
	Toxicology
	Urology

	Medical News
	Awards & Prizes
	Epidemics
	Launch
	Opinion
	Professionals

	Special Topics
	Ethics
	Euthanasia
	Evolution
	Feature
	Odd Medical News
	Climate

Advanced Search

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
	Last Updated: Nov 1, 2009 - 11:48:48 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration Phase

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV).
Jan 18, 2006 - 6:00:37 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin effective in controlling Pancreatic Cancer

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine.
Jan 11, 2006 - 7:20:37 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Peregrine Pharmaceuticals Evaluating Therapeutic Opportunities for Tarvacin

Oct 25, 2005 - 5:10:38 AM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy.
Aug 8, 2005 - 5:39:38 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
New data support broad anti-viral potential of Tarvacin(TM)

The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections.
Jul 31, 2005 - 11:59:38 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) also useful in imaging solid tumors

Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors.
Jul 31, 2005 - 11:12:38 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) to be evaluated for the treatment of Lassa fever

Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections.
Jul 31, 2005 - 11:01:38 PM

<< prev next >>